Atea Pharmaceuticals, Inc is starting a new clinical trial of Study of AT-752 in Patients With Dengue Infection.
The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials
The clinical trial started in April 29, 2022 and will continue throughout January 2023.
Change in DENV viral load from Baseline will be primary outcome measure. To investigate the antiviral activity of AT-752 versus placebo in terms of reduction of DENV RNA from baseline in adult subjects with confirmed DENV infection.
For more details: https://ichgcp.net/clinical-trials-registry/NCT05466240.